NASDAQ · UNCY
Unicycive Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for UNCY: Nov 11, 2026
Unicycive Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.33. The reported EPS for the same quarter last year was $-0.39.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.33 | $-0.23 | $-0.39 | 4 |
| Dec 2026 | $-0.33 | $-0.25 | $-0.39 | 4 |
| Mar 2027 | $-0.04 | $0.44 | $-0.43 | 3 |
| Jun 2027 | $0.23 | $0.49 | $-0.28 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 23, 5:36 AM EDTAverage Analyst Price Target for Unicycive Therapeutics Rises 12.32% to $32.54The average one-year price target for Unicycive Therapeutics (NASDAQCM:UNCY) has been revised to $32.54 / share. This is an increase of 12.32% from the prior estimate of $28.97 dated September 29, 2026. These figures represent aggregate analyst targets and do not constitute a rec
- RTTNews · Oct 21, 9:40 AM EDTUnicycive Jumps As FDA Accepts Kidney Drug Resubmission; March 2027 Decision Set(RTTNews) – Unicycive Therapeutics (UNCY) said the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for hyperphosphatemia in patients with chronic kidney
- Zacks · Oct 13, 8:35 AM EDTUnicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerUnicycive Therapeutics (UNCY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the n
- RTTNews · Sep 29, 9:42 AM EDTUnicycive Resubmits OLC NDA With New Manufacturing Data To Support FDA Review; Stock Down(RTTNews) – Unicycive Therapeutics (UNCY) has resubmitted its New Drug Application (NDA) for oxylanthanum carbonate, seeking FDA approval of the oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
- RTTNews · Sep 29, 9:04 AM EDTUnicycive Therapeutics Resubmits Oxylanthanum Carbonate NDA To FDA(RTTNews) – Biotechnology company Unicycive Therapeutics, Inc. (UNCY) announced Tuesday the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with
- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- RTTNews · Jun 30, 11:51 AM EDTUnicycive Receives FDA Complete Response Letter For Oxylanthanum Carbonate NDA; Stock Down(RTTNews) – Unicycive Therapeutics, Inc. (UNCY), announced that the U.S. FDA issued a Complete Response Letter (CRL) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC), a therapy for hyperphosphatemia in patients with chronic kidney disease (CKD
- RTTNews · Jun 30, 7:34 AM EDTUnicycive Says FDA Issues CRL For Oxylanthanum Carbonate For Hyperphosphatemia In CKD Patients(RTTNews) – Biotechnology company Unicycive Therapeutics, Inc. (UNCY) announced Tuesday that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC) for
- RTTNews · Jun 3, 10:01 AM EDTBiotech Stocks Facing FDA Decision In June 2026(RTTNews) – The month of May saw important regulatory developments, with the FDA approving new therapies for rare and underserved patient populations.
- RTTNews · Jan 29, 7:59 AM ESTUnicycive Therapeutics Announces FDA Acceptance For Resubmitted Oxylanthanum Carbonate NDA(RTTNews) – Unicycive Therapeutics, Inc. (UNCY), Thursday announced the the U.S. Food and Drug Administration has accepted the resubmission of its New Drug Application for oxylanthanum carbonate or OLC, an investigational oral phosphate binder for the treatment of hyperphosphatem
- RTTNews · Dec 29, 7:25 AM ESTUnicycive Resubmits NDA For Oxylanthanum Carbonate To FDA(RTTNews) – Unicycive Therapeutics, Inc. (UNCY) on Monday said it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
- RTTNews · Dec 1, 11:02 PM ESTAfter-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close(RTTNews) – Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Unicycive Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.